Fractional Support as a Service
Embedded expertise for biotech—discovery support, nonclinical strategy, investor‑ready pitch support, and scientific due diligence without the cost of a full‑time hire.
Who we help
Early‑stage biotech & platform startups needing a clear nonclinical plan and leadership before hiring in‑house.
Discovery‑stage & platform teams rationalizing targets, models, and biomarkers.
Academic spinouts translating promising data into development‑quality packages.
Investors & venture studios that require independent scientific/technical diligence.
Clinical‑adjacent teams tightening nonclinical plans to conserve capital and time.
What you get
Discovery & Translational Support
Target identification & prioritization; indication scouting
Mechanism‑of‑action & translational hypothesis; decision criteria
Assay strategy & screening cascade (in vitro, ex vivo, in vivo)
Model selection/validation and biomarker plan (fit‑for‑purpose assays)
PK/PD inputs and dose‑selection hypotheses; data standards & power
Discovery CRO selection/oversight (biology, DMPK, in vivo pharmacology)
Lead optimization guidance; developability & DMPK risk flags
Candidate selection criteria mapped to clinical PoM/PoC
Nonclinical Strategy & IND Planning
Target Product Profile (TPP) and indication fit
Nonclinical roadmap + IND‑enabling study matrix (GLP/GxP aware)
Vendor landscape, CRO RFPs, selection, and oversight
Risk register with mitigation plan, budget, and 12–18‑month timeline
Cross‑functional alignment with CMC, Clinical, and Regulatory
Investor‑Ready Pitch & Fundraising Support
Investor narrative and pitch deck development
Milestone model, use‑of‑funds, and KPI dashboard
Data room structure, checklists, and document QA
Coaching for partner/IC meetings and mock diligence
Scientific & Technical Due Diligence (Buy‑ or Sell‑Side)
Red‑flag screen → deep dive (program, tox, translational rationale)
Feasibility and replication assessment; assumptions and risks
Investment/partnership memo with go/no‑go recommendations
Engagement options
1) Fractional Discovery & Translational Advisor
Own target & indication fit, MoA/translational hypothesis, assay & model strategy, screening cascade, and biomarker plan; oversee discovery CROs and decision logs.
2) Fractional Nonclinical Strategy Lead
Own the TPP and roadmap, design IND‑enabling studies, run CRO selection and oversight, maintain risk/budget/milestones, and deliver board‑ready updates.
3) Fractional Investor Readiness Advisor
Craft the story and deck, build the data room, pressure‑test assumptions, and prepare teams for investor meetings.
4) Fractional Diligence Partner
Independent scientific/technical diligence for investors or partners—from screening to written investment memos.
Mix and match packages to support fundraising windows or IND planning sprints.
Outcomes we deliver
Clear discovery strategy: target/indication fit, mechanism hypothesis, and screening cascade
Validated models and biomarker plan tied to human endpoints
Early developability/DMPK risk flags and candidate selection criteria
Decision‑grade nonclinical roadmaps tied to a clear TPP and indication rationale
IND‑enabling study plans that balance risk, cost, and time
Investor‑ready pitch decks and data rooms that withstand scrutiny
Independent diligence memos with risks, mitigations, and go/no‑go calls
FAQs
What’s the difference between fractional and hourly consulting?
Fractional = embedded ownership with recurring leadership time; hourly = ad‑hoc advice.
Can you act as Interim Head of Discovery or Nonclinical?
Yes—scope typically includes roadmap, study design, CRO oversight, and cross‑functional alignment (no legal/regulatory representation).
Do you run wet‑lab experiments?
No—we don’t operate a lab. We design studies, select/oversee CROs/academic labs, review protocols and data, and ensure decision‑grade outputs.
Which modalities do you support?
Modality‑agnostic: small molecules, biologics, peptides, RNA/oligo, cell and gene therapies.
Do you mark up vendors?
No. We are vendor‑agnostic and do not take referral fees.
How quickly can we start?
Usually within 1–2 weeks of agreement; we can prioritize urgent diligence windows.
Geography & time zones?
Remote‑first; support roles worldwide.
Confidentiality & conflicts?
We sign mutual NDA, disclose potential conflicts, and avoid competing claims. All deliverables are client‑owned.